Limitations of NCCN PD-L1 Expression Recommendations

Video content above is prompted by the following:

• How could emergingoverall survival data from trials like POSEIDON and KEYNOTE-189 impact future treatment guidelines and our understanding of long-term outcomes?

• What evidence supports using dual checkpoint inhibitor therapy plus chemotherapy over chemotherapy alone in the first-line driver-negative setting?